Navigation Links
Pharmacyclics Identifies Functional Biomarkers for its Novel HDAC,Inhibitor and Demonstrates Preclinical Anti-Tumor Activity with,Bruton's Tyrosine Kinase Inhibitors

SUNNYVALE, Calif. and LOS ANGELES, April 18, 2007 /PRNewswire-FirstCall/ -- Pharmacyclics, Inc. today announced data from two preclinical studies, one identifying a functional biomarker for its novel histone deacetylase (HDAC) inhibitor and another demonstrating preclinical anti-tumor activity with its Bruton's tyrosine kinase (BTK) inhibitor compounds. The data were presented at the American Association for Cancer Research (AACR) 2007 Annual Meeting being held this week in Los Angeles.

Results of an in vitro study (Abstract #1966) demonstrate that Pharmacyclics' HDAC inhibitor, PCI-24781 inhibits homologous recombination, a cellular mechanism of DNA repair, by both down-regulating RAD51 gene expression, and by affecting the ability of the cell to form RAD51 foci at the site of the lesion. The RAD51 gene provides instructions for making a protein that is essential for the repair of damaged DNA. These data suggest that PCI- 24781 could be used successfully in combination with other cancer therapies that generate lesions repaired by homologous recombination, such as gamma- irradiation, cisplatin, and oxaliplatin, and show the usefulness of using RAD51, an enzyme, as a biomarker to predict clinical efficacy. Researchers observed that PCI-24781-treated cells are more sensitive to DNA damaging cancer agents, suggesting that it may act in part by inhibiting DNA repair. PCI-24781 is currently in Phase 1 clinical trials evaluating its safety and effectiveness in both solid and hematological malignancies.

"Not only have we further elucidated the mechanism by which our HDAC inhibitor may kill cancer cells, we have also identified a biomarker that may predict its efficacy in cancer patients," stated Richard A. Miller, M.D., president and CEO of Pharmacyclics. "We have filed patents based on this new information, and are moving this promising compound forward in clinical trials incorporating use of this bioma rker."

In a separate study, researchers tested the effects of Pharmacyclics' BTK inhibitor, PCI-31523, on a variety of B cell receptor (BCR) -expressing lymphoma cell lines. Because many lymphomas require an intact BCR for survival, they should be uniquely sensitive to drugs that target the BCR pathway. Results of the study (Abstract #5398) demonstrated that multiple diffuse large B cell lymphoma lines and follicular lymphoma lines are sensitive to PCI-31523, with growth arrest and apoptosis occurring at concentrations as low as 0.5uM.

In other studies, oral dosing of PCI-31523 (10mg/kg qd) resulted in almost complete inhibition of inflammation in an animal model of arthritis, indicating that this compound may be effective in both autoimmune disease and lymphoma.

About HDAC Inhibition and Cancer

Histone deacetylase (HDAC) inhibitors are a new class of anticancer drugs that modulate transcriptional activity in cells and may thus block angiogenesis and cell cycling, key components of tumor proliferation. HDAC inhibitors also appear to promote apoptosis (cell death) and differentiation. These compounds also may improve the efficacy of existing cancer therapies and, because they target the transcription of specific disease-causing genes, may offer new therapeutic approaches to cancer therapy.

About Bruton's Tyrosine Kinase and Immune Diseases

B-cells are immune cells, which are activated by antigens, pathogens or, in the case of autoimmunity, by host tissues. B-cells produce antibodies, which when self-reactive can trigger autoimmune disease. Activation of B-cells is also thought to play a major role in lymphomas where continuous, or tonic, stimulation results in uncontrolled B-cell proliferation. BTK is a tyrosine kinase inside B-cells that plays an early key role in B-cell activation. Drugs that can inhibit BTK may prevent B-cell activation and therefore may play a role in treatment of lymphomas or autoimmune disease. Other ty rosine kinases are important in cell signaling and have been targets for other drugs such as imatanib mesylate (Gleevec(R)), which is approved for treatment of certain leukemias. New drug or biological candidates targeting B-cells, including the recently approved rituximab (Rituxan(R)) for lymphomas and rheumatoid arthritis, are aimed at eliminating abnormally functioning B-cells.

About Pharmacyclics

Pharmacyclics is a pharmaceutical company developing innovative products to treat cancer and other serious diseases. The company is leveraging its small-molecule drug development expertise to build a pipeline in oncology and other diseases based on a wide range of targets, pathways and mechanisms. Its lead product, Xcytrin(R) (motexafin gadolinium) Injection, has completed Phase 3 clinical trials and several ongoing Phase 1 and Phase 2 clinical trials are evaluating Xcytrin as a single agent or in combination with chemotherapy and/or radiation in multiple cancer types. More information about the company, its technology, and products can be found at www.pharmacyclics.com. Pharmacyclics(R), Xcytrin(R) and the "pentadentate" logo(R) are registered trademarks of Pharmacyclics, Inc.

Gleevec(R) is a registered trademark of Novartis.

Rituxan(R) is a registered trademark of Genentech and Biogen Idec.

NOTE: Other than statements of historical fact, the statements made in this press release about plans for our NDA filing, enrollment and future plans for our clinical trials, progress of and reports of results from preclinical and clinical studies, clinical development plans and product development activities are forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995. The words "believe," "will," "may," "continue," "plan," "expect," "intend," "anticipate," variations of such words, and similar expressions also identify forward-looking statements, b ut their absence does not mean that the statement is not forward-looking. The forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that may cause actual results to differ materially from those in the forward-looking statements. Factors that could affect actual results include risks associated with the initiation, timing, design, enrollment and cost of clinical trials; unexpected delays in clinical trials; the fact that data from preclinical studies and Phase 1 or Phase 2 clinical trials may not necessarily be indicative of future clinical trial results; our ability to obtain future financing and fund the product development of our pipeline; our ability to establish successful partnerships and collaborations with third parties; the regulatory approval process in the United States and other countries; and our future capital requirements. For further information about these risks and other factors that may affect the actual results achieved by Pharmacyclics, please see the company's reports as filed with the U.S. Securities and Exchange Commission from time to time, including but not limited to its annual report on Form 10-K for the period ended June 30, 2006 and its subsequently filed quarterly reports on Form 10-Q. Forward-looking statements contained in this announcement are made as of this date, and we undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

CONTACT: Leiv Lea of Pharmacyclics, Inc., +1-408-774-0330; or CarolynBumgardner Wang of WeissComm Partners, +1-415-946-1065, for Pharmacyclics,Inc.

Web site: http://www.pharmacyclics.com/

Ticker Symbol: (NASDAQ-NMS:PCYC)

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company< /font>


'"/>




Related medicine technology :


1. Pharmacyclics Announces Interim Results From Two Ongoing Phase 2 Trials Supporting Potential of Xcytrin Plus Chemotherapy to Treat Recurrent Non-Small Cell Lung Cancer
2. Pharmacyclics Announces Promising Results From Phase 2 Clinical Trial of Xcytrin in Recurrent, Metastatic Non-Small Cell Lung Cancer
3. Pharmacyclics Announces Presentations and Published Abstracts on Xcytrin at The 2007 American Society of Clinical Oncology Annual Meeting
4. Pharmacyclics Announces Presentations on Its Novel and Selective HDAC and Brutons Tyrosine Kinase Inhibitor Compounds
5. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
6. Anacor Identifies a Novel Mechanism for Its Lead Anti-Fungal Drug, AN2690; Findings Published in Science
7. ARRIVE Registry Analysis Identifies Predictors of Stent Thrombosis in Real-World Use of Drug-Eluting Stents
8. NIDA Study Identifies Genes That Might Help Some People Abstain from Smoking
9. Rigel Ubiquitin Ligase Program Identifies Molecules With Anti-HIV Activity
10. Study in Cell by Magen BioSciences Co-Founder David E. Fisher Identifies New Roles in Skin Cancer Prevention for Key Tumor Suppressor Protein
11. BioLineRx Presents Data on BL-1040 at Cardiovascular Revascularization Therapies Conference Demonstrating Potential to Reduce Deterioration of Infarcted Heart Tissue and Maintain Functionality
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... June 24, 2016  Arkis BioSciences, a leading ... and more durable cerebrospinal fluid treatments, today announced ... Series-A funding is led by Innova Memphis, followed ... other private investors.  Arkis, new financing will accelerate ... the market release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... 23, 2016 Research and Markets has ... - Forecast to 2022" report to their offering. ... for the patients with kidney failure, it replaces the function ... the patient,s blood and thus the treatment helps to keep ... in balance. Increasing number of ESRD patients ...
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... the "Pharmaceutical Excipients Market by Type (Organic Chemical ... Preservative), Formulation (Oral, Topical, Coating, Parenteral) - Global Forecast ... The global pharmaceutical excipients ... 2021 at a CAGR of 6.1% in the forecast ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... June 26, 2016 , ... ... they have been diagnosed with endometriosis. These women need a treatment plan to ... a comprehensive approach that can help for preservation of fertility and ultimately achieving ...
(Date:6/25/2016)... , ... June 25, 2016 , ... First Choice ... States, named Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm ... Medical Director of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical ...
(Date:6/24/2016)... ... 24, 2016 , ... A recent article published June 14 on ... article goes on to state that individuals are now more comfortable seeking to undergo ... such as calf and cheek reduction. The Los Angeles area medical group, Beverly Hills ...
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg ... Legal Elite. The attorneys chosen by their peers for this recognition are considered among ... Greenberg Traurig Shareholders received special honors as members of this year’s Legal Elite Hall ...
(Date:6/24/2016)... ... 2016 , ... EB Medicine presented its first-ever “Issue of ... in Ponte Vedra Beach, FL. The awards honor the outstanding work of leading ... and Pediatric Emergency Medicine Practice. , “With this award, we recognize the efforts ...
Breaking Medicine News(10 mins):